Medarex To Start Pivotal Trial Of MDX-010/Cancer Vaccine Combo For Melanoma

The company plans a Subpart E filing as early as 2006 based on response rate data from the Phase III study, designed under a special protocol assessment with FDA. The immune-boosting MDX-010/MDX-1349 combination trial will start enrolling patients in September.